Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 502-508

  Sundar, S ^a   Symonds, R P ^b   Decatris, M P ^b   Kumar, D M ^b   Osman, A ^b   Vasanthan, S ^b   O'Byrne, K J ^c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Chemotherapy; Fluorouracil; Ovarian cancer; Oxaliplatin; Phase II; Platinum resistance

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; KIDNEY FUNCTION; LETHARGY; LEUKOPENIA; LIVER FUNCTION; LONG TERM CARE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; SENSITIVITY ANALYSIS; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 3543147160     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.04.020     Document Type: Article

References (45)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52(1):2002;23-47
2. Ferlay J., Bray F., Pisani P., Parkin D. GLOBOSCAN-2000: cancer incidence, mortality and prevalence worldwide, version 1.0. International agency for research on cancer. 2001;IARC Press, Lyon, France
3. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 329(21):1993;1550- 1559
4. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20(5):2002;1248-1259
5. ICON3: paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 360(9332):2002;505-515
6. Ozols R.F. Gynecologic oncology group trials in ovarian carcinoma. Semin. Oncol. 24(1 Suppl 2):1997;S2-10-S2-12
7. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 5(1):2000;26-35
8. Culy C.R., Clemett D., Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 60(4):2000;895-924
9. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 52(12):1996;1855-1865
10. Pendyala L., Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53(24):1993;5970-5976
11. Mathe G., Kidani Y., Segiguchi M., Eriguchi M., Fredj G., Peytavin G., et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43(4):1989;237-250
12. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1):2004;23-30
13. Wilson A.P., Ford C.H., Newman C.E., Howell A. Cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. Br. J. Cancer. 56(6):1987;763-773
14. de Gramont A., Drolet Y., Louvet C., Dray C., Krulik M., Pigne A., et al. Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hotel-Dieu of Quebec and Hopital Saint-Antoine (Paris). J. Gynecol. Obstet. Biol. Reprod. 15(1):1986;105-109
15. Barlow J.J., Lele S.B., Emrich L.J. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection. Am. J. Obstet. Gynecol. 152(3):1985;310-314
16. Look K.Y., Blessing J.A., Muss H.B., DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the gynecologic oncology group. Am. J. Clin. Oncol. 15(6):1992;494-496
17. Look K.Y., Muss H.B., Blessing J.A., Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. 18(1):1995;19-22
18. Rustum Y.M. Clinical implications of 5-FU modulation. Oncology (Huntingt.). 13(7 Suppl 3):1999;22-25
19. Extra J.M., Marty M., Brienza S., Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 25(2 Suppl 5):1998;13-22
20. Bleiberg H., de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin. Oncol. 25(2 Suppl 5):1998;32-39
21. de Braud F., Munzone E., Nole F., De Pas T., Biffi R., Brienza S., et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am. J. Clin. Oncol. 21(3):1998;279-283
22. Kerr D.J., Gray R., McConkey C., Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules-less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann. Oncol. 11(8):2000;947-955
23. Fischel J.L., Etienne M.C., Formento P., Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin. Cancer Res. 4(10):1998;2529-2535
24. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92(3):2000;205-216
25. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47(1):1981;207-214
26. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14(5):1996;1545-1551
27. R. Lowry, VassarStats: Website for Statistical Computation. http://faculty.vassar.edu/lowry/VassarStats.html (accessed on 05 Jan 2004).
28. Rustin G.J., Nelstrop A.E., Tuxen M.K., Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann. Oncol. 7(4):1996;361-364
29. Guppy A.E., Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 7(5):2002;437-443
30. Cannistra S.A. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J. Clin. Oncol. 20(5):2002;1158-1160
31. Misset J.L., Kidani Y., Gastiaburu J. Oxalatoplatinum (L-OHP): experimental and clinical studies. Howell S. Platinum and other metal coordination compounds in cancer chemotherapy. 1991;369-375 Plenum, New York
32. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92(9):2000;699-708
33. Piccart M.J., Green J.A., Lacave A.J., Reed N., Vergote I., Benedetti-Panici P., et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European organization for research and treatment of cancer gynecology group. J. Clin. Oncol. 18(6):2000;1193-1202
34. Chollet P., Bensmaine M.A., Brienza S., Deloche C., Cure H., Caillet H., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 7(10):1996;1065-1070
35. Dieras V., Bougnoux P., Petit T., Chollet P., Beuzeboc P., Borel C., et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann. Oncol. 13(2):2002;258-266
36. Misset J.L., Vennin P., Chollet P.H., Pouillart P., Laplaige P.H., Frobert J.L., et al. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann. Oncol. 12(10):2001;1411-1415
37. Delaloge S., Laadem A., Taamma A., Chouaki N., Cvitkovic E., Pautier P., et al. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am. J. Clin. Oncol. 23(6):2000;569-574
38. Faivre S., Bourdon O., Bensmaine M., Extra J., Gautier H., Cvitkovic E., et al. Paclitaxel (TXL)/oxaliplatin (LOHP) association in pretreated recurrent ovarian carcinoma (ROC) patients. Proc. Am. Soc. Clin. Oncol. 17:1997
39. Soulie P., Bensmaine A., Garrino C., Chollet P., Brain E., Fereres M., et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur. J. Cancer. 33(9):1997;1400-1406
40. Fracasso P., Blessing J.A., Morgan M.A., Sood A.K., Hoffman J.S. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group study. J. Clin. Oncol. 21(15):2003;2856-2859
41. Pentheroudakis G., Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res. 22(6B):2002;3589-3596
42. Hata K., Kamikawa T., Arao S., Tashiro H., Katabuchi H., Okamura H., et al. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br. J. Cancer. 79(11-12):1999;1848-1854
43. Boehmer C., Jaeger W. Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res. 22(1A):2002;439-443
44. Diaz-Rubio E., Evans T.R., Tabemero J., Cassidy J., Sastre J., Eatock M., et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann. Oncol. 13(4):2002;558-565
45. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1):1997;110-115